Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-12-08 DOI:10.1080/14737140.2023.2272645

Gyula Ostoros, Robert Hettle, Nefeli Georgoulia, Mehmet Berktas, Pratibha Chander, Ignacio Diaz Perez, Anne-Marie Couto, Christian Eichinger, Polly Field, Peter Morten

{"title":"Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis.","authors":"Gyula Ostoros, Robert Hettle, Nefeli Georgoulia, Mehmet Berktas, Pratibha Chander, Ignacio Diaz Perez, Anne-Marie Couto, Christian Eichinger, Polly Field, Peter Morten","doi":"10.1080/14737140.2023.2272645","DOIUrl":null,"url":null,"abstract":"Background: We wanted to evaluate if event-free survival (EFS) is a reliable surrogate for overall survival (OS) in patients with resectable non-small cell lung cancer (r-NSCLC) receiving neoadjuvant therapy. We conducted a systematic literature review and meta-analysis to investigate the statistical association between EFS and OS.Research design and methods: Electronic databases were searched on 30 July 2021 to identify sources reporting both EFS and OS data in patients with stage I-IIIB r-NSCLC receiving neoadjuvant therapy. Correlation and regression analyses evaluated the association between the effect of treatment on EFS and OS using log-hazard ratios (HRs). Sources in which the entire population had epidermal growth factor receptor mutations were excluded from the analyses.Results: We identified 74 sources, of which 8 reported EFS and OS HRs from randomized controlled trials. Based on these, we found a positive linear correlation and a strong association between EFS and OS log-HRs (weighted Pearson's correlation coefficient r = 0.864; 95% confidence interval 0.809-0.992; P = 0.006; random-effects meta-regression, R2 = 0.777).Conclusions: We found a strong association between treatment effects for EFS and OS, indicating that improvements in EFS are likely to be predictive of improvements in OS. EFS may therefore be a reliable surrogate for OS after neoadjuvant therapy in r-NSCLC.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1305-1313"},"PeriodicalIF":2.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2023.2272645","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We wanted to evaluate if event-free survival (EFS) is a reliable surrogate for overall survival (OS) in patients with resectable non-small cell lung cancer (r-NSCLC) receiving neoadjuvant therapy. We conducted a systematic literature review and meta-analysis to investigate the statistical association between EFS and OS.

Research design and methods: Electronic databases were searched on 30 July 2021 to identify sources reporting both EFS and OS data in patients with stage I-IIIB r-NSCLC receiving neoadjuvant therapy. Correlation and regression analyses evaluated the association between the effect of treatment on EFS and OS using log-hazard ratios (HRs). Sources in which the entire population had epidermal growth factor receptor mutations were excluded from the analyses.

Results: We identified 74 sources, of which 8 reported EFS and OS HRs from randomized controlled trials. Based on these, we found a positive linear correlation and a strong association between EFS and OS log-HRs (weighted Pearson's correlation coefficient r = 0.864; 95% confidence interval 0.809-0.992; P = 0.006; random-effects meta-regression, R² = 0.777).

Conclusions: We found a strong association between treatment effects for EFS and OS, indicating that improvements in EFS are likely to be predictive of improvements in OS. EFS may therefore be a reliable surrogate for OS after neoadjuvant therapy in r-NSCLC.

查看原文本刊更多论文

癌症新辅助治疗后无事件生存率与总生存率的相关性：系统综述和荟萃分析。

背景：我们想评估接受新辅助治疗的可切除癌症（r-NSCLC）患者的无事件生存率（EFS）是否是总生存率（OS）的可靠替代品，我们进行了系统的文献回顾和荟萃分析，以调查EFS和OS之间的统计相关性。研究设计和方法：于2021年7月30日搜索电子数据库，以确定报告接受新辅助治疗的I-IIIB期r-NSCLC患者EFS和OS数据的来源。相关和回归分析使用对数危险比（HR）评估了EFS和OS治疗效果之间的相关性。所有人群都有表皮生长因子受体突变的来源被排除在分析之外。结果：我们确定了74个来源，其中8个报告了随机对照试验中的EFS和OS HR。在此基础上，我们发现EFS和OS log HR之间存在正线性相关性和强相关性（加权Pearson相关系数r = 0.864；95%置信区间0.809-0.992；P = 0.006；随机效应元回归，R2 = 0.777）。结论：我们发现EFS的治疗效果与OS之间有很强的相关性，表明EFS的改善可能预示着OS的改善。因此，EFS可能是r-NSCLC新辅助治疗后OS的可靠替代品。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.